Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial

Bisi, 2016, Preclinical characterization of G1T28: a novel CDK4/6 inhibitor for reduction of chemotherapy-induced myelosuppression, Mol Cancer Ther, 15, 783, 10.1158/1535-7163.MCT-15-0775 He, 2017, Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion, Sci Transl Med, 9, eaal3986, 10.1126/scitranslmed.aal3986 Johnson, 2010, Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibition, J Clin Invest, 120, 2528, 10.1172/JCI41402 Roberts, 2012, Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy, J Natl Cancer Inst, 104, 476, 10.1093/jnci/djs002 Deng, 2018, CDK4/6 inhibition augments antitumor immunity by enhancing T-cell activation, Cancer Discov, 8, 216, 10.1158/2159-8290.CD-17-0915 Lai, 2018, Abstract 1752: transient exposure of trilaciclib, a CDK4/6 inhibitor, modulates gene expression in tumor immune infiltrates to promote a pro-inflammatory tumor microenvironment, Cancer Res, 78, 1752, 10.1158/1538-7445.AM2018-1752 Sorrentino, 2017, Abstract 5628: trilaciclib (G1T28), a CDK4/6 inhibitor, enhances the efficacy of combination chemotherapy and immune checkpoint inhibitor treatment in preclinical models, Cancer Res, 77, 5628, 10.1158/1538-7445.AM2017-5628 George, 2015, Comprehensive genomic profiles of small cell lung cancer, Nature, 524, 47, 10.1038/nature14664 Brown, 2014, 1 Kim, 2013 Arbuck, 1986, Etoposide pharmacokinetics in patients with normal and abnormal organ function, J Clin Oncol, 4, 1690, 10.1200/JCO.1986.4.11.1690 Elferink, 1987, Pharmacokinetics of carboplatin after i.v. administration, Cancer Treat Rep, 71, 1231 Kaul, 1995, Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors, J Clin Oncol, 13, 2835, 10.1200/JCO.1995.13.11.2835 van der Vijgh, 1991, Clinical pharmacokinetics of carboplatin, Clin Pharmacokinet, 21, 242, 10.2165/00003088-199121040-00002 Weiss, 2019, Positive effects of trilaciclib on patient myelosuppression-related symptoms and functioning: results from three phase 2 randomized, double-blind, placebo-controlled small cell lung cancer trials, Support Care Cancer, 27, S274 O'Shaughnessy, 2019, Trilaciclib (T), a CDK4/6 inhibitor, dosed with gemcitabine (G), carboplatin (C) in metastatic triple negative breast cancer (mTNBC) patients: preliminary phase 2 results, Cancer Res, 79, 10.1158/1538-7445.SABCS18-PD1-01